Clinical collaboration
OncoCore is under active development, and its next step cannot be taken in a laboratory: we need oncology services, molecular pathology units and hospital pharmacy teams to evaluate it with real cases, in their own workflow and with their critical eye. That evaluation is what turns a technically sound system into a tool that is genuinely useful in the board session.
The collaboration works because each side contributes what the other does not have: the service brings clinical reality, and Sphera brings the tool and the team that builds it.
OncoCore's current clinical scope is NSCLC because it is the setting where the problem we address is most concentrated: a broad and growing arsenal of targeted therapies, biomarkers that change the indication (mutations, fusions, TMB, MSI, PD-L1) and guidelines that are updated frequently. It is where the mismatch between data volume and analysis time is sharpest, and therefore where the tool can demonstrate its value soonest.
Starting with a single subtype is a deliberate choice of rigour: we prefer a consolidated, evaluable knowledge base in one domain to broad but superficial coverage. Extension to other tumours will follow, prioritised together with collaborating teams.
Four steps, from the first conversation to the analysis of results. With no commitment to continue: the purpose of the evaluation is to learn, not to close a sale.
We present OncoCore around a practical NSCLC case and answer the team's questions, both clinical and technical.
Together with the service we agree what is evaluated, with which cases, over what period and against which criteria.
We adjust formats and logic to the centre's protocols and deploy on the agreed infrastructure.
We review the evaluation results together and carry the conclusions into the product roadmap.
The evaluation is framed as an assessment of the tool, not as clinical use: board decisions are taken through the centre's usual procedures, and OncoCore's output is compared retrospectively or in parallel, as agreed.
Data processing complies with the General Data Protection Regulation and the centre's procedures, with the minimisation and pseudonymisation measures set out in our design principles.
We formalise the collaboration with whatever agreements each institution requires (confidentiality, data processing, collaboration agreement), fitting into their approval pathways.
Tell us which service you work in and what you would like to evaluate. We will suggest an initial video call with a demonstration on a practical NSCLC case.
Sphera OncoCore is a platform under development, intended for research and clinical evaluation purposes. It does not hold CE marking as a medical device and is not intended for use as a diagnostic or prescribing tool. Every clinical decision remains the responsibility of the treating healthcare professional.
